The frequency of expression of almost all immune markers, except for CD73 on CD4+ T cells, was higher in the tumor microenvironment than in PBMCs from patients with GBM and PBMCs from healthy donors (Figure 2, C and D). The gene discussed is CD4; the disease is glioblastoma.